法舒地尔在慢性阻塞性肺疾病急性加重期伴肺动脉高压患者中的应用

目的：观察法舒地尔治疗慢性阻塞性肺疾病急性加重期伴肺动脉高压患者的临床疗效。方法将70例慢性阻塞性肺疾病急性加重期伴肺动脉高压患者遵循随机数字表格法分为对照组35例，接受常规治疗，观察组35例，在常规治疗的基础上接受法舒地尔治疗，疗程为2周。记录并比较两组患者治疗前后的肺动脉收缩压、健康生活质量评分以及6 min步行试验（6-MWT）。结果治疗2周后，观察组患者的肺动脉收缩压与治疗前相比明显降低，6-MWT明显上升，此外，观察组患者在治疗后的健康生活质量评分显著高于治疗前，且差异均具有统计学意义（P〈0.05）；治疗后两组患者6-MWT均有所升高，但观察组明显优于对照组，两组患者在治疗后的肺动脉收缩压均明显下降，但观察组的下降幅度要高于对照组，其差异均有统计学意义（P〈0.05）；两组的健康生活质量评分比较，在精神健康及精力方面比较差异有统计学意义（P〈0.05），其他指标则差异无统计学意义（P〉0.05）。结论法舒地尔治疗慢性阻塞性肺疾病急性加重期伴肺动脉高压效果良好，值得临床推广使用。

Application of fasudil in patients with acute exacerbation of chronic obstructive pulmonary disease accompany by pulmonary hypertension

Objective To observe the clinical curative effect of fasudil hydrochloride in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease accompany by pulmonary hypertension. Methods By using a random number table, 70 cases were divided into a control group with 35 patients who received conventional treatment, and an observation group with 35 cases who accepted fasudil treatment on the basis of conventional therapy. All patients were treated for two weeks. Healthy quality of life score, pulmonary artery systolic pressure, and six-minute walk test （6-MWT） results before and after treatment were recorded and analyzed. Results After 2 weeks of treatment, compared with those before treatment, the observation group showed a decrease in pulmonary arterial systolic pressure and an increase in 6-MWT and healthy quality of life scores with statistical differences （P〈0.05）. After treatment, 6-MWT increased in both groups, but the increasing in the observation group was greater than that in the control group. The pulmonary artery systolic pressure decreased in both groups, but the decrease in the observation group was greater, with a statistical difference （P〈0.05）. As to healthy quality of life scores, there were differences in energy, mental health indexes between the two groups （P〈0.05）, and there was no difference in other indexes （P〉0.05）. Conclusion Fasudil shows good effects on the treatment of patients with acute exacerbation of chronic ob-structive pulmonary disease accompany by pulmonary hypertension. Therefore, it is worthy of clinical use.